Skip to main content

Table 2 Key events in the discovery of the first two waves of epigenetic drugs

From: The timeline of epigenetic drug discovery: from reality to dreams

  DNA methyltransferase inhibitors
1964 Azacitidine and decitabine synthesis
1967 Azacitidine enters clinical trials
1980 Azacitidine and decitabine identified as DNMT inhibitors
1980 Decitabine enters clinical trials
2004 Azacitidine FDA approval
2006 Decitabine FDA approval
  Histone deacetylase inhibitors
1971 DMSO reported as differentiation agent
1976 Bisamide precursor to SAHA (vorinostat) reported as differentiation agent
1990 Trichostatin A identified as HDAC inhibitor
1990 Romidepsin reported as a natural product
1996 Vorinostat synthesis
1997 Romidepsin enters clinical trials
1998 Vorinostat and romidepsin identified as HDAC inhibitors
2000 Vorinostat enters clinical trials
2006 Vorinostat FDA approval
2009 Romidepsin FDA approval
2014 Belinostat FDA approval
2015 Panobinostat FDA approval
2015 Chidamide China’s FDA approval